Revenue segments as reported by the company.

Nutrition

Diagnostics

Established Pharmaceuticals

Medical Devices

Other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Amortization of intangible assets

Research and development

Selling, general, and administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Abbott Labs

St. Jude Medical was an American global medical device company headquartered in Little Canada, Minnesota, U.S., a suburb of Saint Paul. The company had more than 20 principal operations and manufacturing facilities worldwide with products sold in more than 100 countries. The company was acquired by Abbott Laboratories in January 2017.

St. Jude Medical

Abbott Laboratories engages in the discovery, development, manufacture, and sale of health care products. It operates through the following business segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment refers to the international sales of a line of branded generic pharmaceutical products. The Diagnostic Products segment markets diagnostic systems and tests for blood banks, hospitals, commercial laboratories, and alternate-care testing sites. The Nutritional Products segment caters to the worldwide sales of adult and pediatric nutritional products. The Medical Devices segment includes electrophysiology, heart failure, vascular and structural heart devices for the treatment of cardiovascular diseases, and diabetes care products for people with diabetes, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company was founded by Wallace Calvin Abbott in 1888 and is headquartered in Abbott Park, IL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Abbott Labs reports solid Q4 performance and eyes growth opportunities

Abbott Labs delivered a strong performance in Q4 2022, showcasing resilience and strategic focus amidst challenges in certain business segments.
The company's emphasis on innovation, product excellence, and market expansion positions it well for future growth and success.
While facing challenges like inflation and market restrictions, Abbott is actively pursuing opportunities for growth through new product launches and strategic investments.
Investors can be optimistic about Abbott's outlook for 2023, with a positive trajectory in sales, product development, and cash use priorities.

Abbott Labs surpasses Q1 earnings estimates, eyes growth opportunities

Abbott Labs exceeded earnings expectations with strong organic sales growth. Performance driven by Medical Devices, Established Pharmaceuticals, and Nutrition segments. Challenges include lower Diagnostics sales and uncertainties around COVID testing.

Abbott Labs excels in Q2 with strong sales growth and innovation

Abbott Labs delivered a strong performance in Q2 2023, driven by robust organic sales growth, successful product launches, and strategic market expansion initiatives across key business segments.
Despite challenges related to COVID testing demand decline and exchange rate impacts, Abbott's focus on innovation, market share recovery, and operational efficiency positions it well for sustained growth and profitability.
The company's strengths in diverse product offerings, market leadership in key segments, and opportunities for further expansion and innovation underscore its resilience and strategic vision in the healthcare industry.
By navigating challenges, leveraging strengths, and capitalizing on opportunities, Abbott is poised to maintain its growth trajectory, drive market leadership, and deliver value to shareholders and stakeholders.

Abbott Labs excels in Q3, eyes growth in China and innovation

Abbott Labs delivered robust performance across key segments, positioning well for sustained growth.
The company showcased strong sales growth, user adoption, and strategic readiness for future opportunities.
While challenges exist in market dynamics and cost management, Abbott remains optimistic about its outlook.
Overall, Abbott's Q3 results reflect a resilient business model and a focus on innovation and growth.

Abbott Labs surpasses 2023 expectations, poised for strong 2024 growth

Abbott Labs delivered impressive performance in 2023, exceeding expectations and showcasing strength across key segments. The company's diversified business model and strategic investments position it well for continued growth in 2024. Abbott's focus on sustainable growth, market share expansion, and innovation bode well for its future.

Abbott Labs excels in Q1, raises guidance on strong performance

Abbott Labs delivered a standout quarter with robust financial performance, strategic product launches, and optimistic guidance updates. Despite facing FX challenges, the company remains well-positioned for growth through innovation and market expansion.

Abbott Labs excels in Q2, raises guidance amid strong segment performance

Abbott Labs' Q2 performance reflects strong growth momentum across segments and strategic focus on innovation and market expansion.
The company's strengths in Nutrition, Diagnostics, and Medical Devices position it well for sustained growth and value creation.
While facing challenges such as ongoing litigation, Abbott Labs remains poised to capitalize on opportunities in biosimilars, new product approvals, and market expansion.

Abbott Labs excels in Q3 with strong sales growth and strategic advancements

Abbott Labs demonstrated robust financial performance and strategic advancements in Q3 2024, showcasing resilience and innovation. While facing potential challenges ahead, the company's diverse portfolio and market-leading products position it well for future growth and success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

ABBOTT PARK, Ill., Aug. 3, 2021 /PRNewswire/ -- Abbott (NYSE: ABT) today announced it has received U.S. Food and Drug Administration (FDA) clearance for its latest optical coherence tomography (OCT) imaging platform powered by the company's new Ultreon Software.

Abbott Receives FDA Clearance for its Imaging Technology Using Artificial Intelligence for Vessels in the Heart

Two units of Abbott Laboratories will pay $160 million to resolve claims they violated the federal False Claims Act by submitting false claims to Medicare, the U.S. Department of Justice said on Monday.

U.S. says Abbott units to pay $160 million to resolve alleged false Medicare claims

ABBOTT PARK, Ill., Aug. 2, 2021 /PRNewswire/ -- Abbott announced today that the U.S. Food and Drug Administration (FDA) has cleared the FreeStyle® Libre 2 iOS application for use with compatible iPhones1, providing a comprehensive digital offering for its FreeStyle Libre 2 integrated continuous glucose monitoring (iCGM) system.

Abbott's FreeStyle® Libre 2 iOS App Cleared in U.S., Providing a Seamless Digital Experience to Simplify Diabetes Management

ABBOTT PARK, Ill., July 29, 2021 /PRNewswire/ -- A new study conducted by The Ohio State University and Abbott (NYSE: ABT) showed that half of the adults surveyed living with diabetes did not consume the daily recommended intake of protein, which is associated with lower diet quality, increased carbohydrate intake, and greater physical limitations.

New Study: Half of Americans Living with Diabetes May be Consuming Less Than the Recommended Amount of Protein, which is Associated with Greater Physical Limitations

Becton, Dickinson and Co.

Johnson & Johnson

You shouldn't invest your life savings into any one stock, but these three have some serious potential.

3 Dividend Stocks Safe Enough to Bet the Farm On

Novavax

You have the power to turn a negative event into something positive.

Anxious About a Market Crash? Start Doing These 3 Things Right Now

Intuitive Surgical

What healthcare executives are saying so far about the impact of the coronavirus variant on their businesses is reassuring.

Worries About the Delta Variant Could Be Overdone Based on Clues From These Healthcare Giants

The shares of Abbott Laboratories (NYSE: ABT) have received a price target increase from $116 to $128 by Raymond James. These are the details.

ABT Stock $128 Target From Raymond James

Abbott Laboratories' stock was in a short-term downtrend, but continuing accumulation appears likely in the second half of 2021. Abbott recently reported earnings, which were decent, but shares sold off anyway. They quickly reversed to close the week at prices last seen in April.

Abbott Laboratories Is Likely To Melt Up Into 2022

Apple

Butterfly Network

Globus Medical

HealthCor Catalio Acquisition Corp

A look at a new SPAC in the healthcare business with great long-term potential.

The Next Nano-X, but With Less Risk?

The US medical devices company Abbott Laboratories (NYSE:ABT) announced its fiscal Q2 results on Thursday before markets opened. The company posted higher than expected revenue of $10.22 billion, beating the consensus Street estimate by $550 million.

Abbott Labs stock price forecast for Q3 after Q2 results

Ford Motor Company

Abbott Laboratories (ABT) CEO, Robert Ford on Q2 2021 Results - Earnings Call Transcript

Abbott's (ABT) Adult Nutrition sales benefit from improved sales performance of complete and balanced nutrition brand Ensure and diabetes nutrition brand, Glucerna in Q2.

Abbott (ABT) Q2 Earnings Beat, Molecular Diagnostic Sales Drop

Canaan Inc.

Check Point Software Technologies

Clorox

Canadian National Railway Company

Infosys

McCormick

NextEra Energy

NewMarket

Novo Nordisk

Taiwan Semiconductor Manufacturing

Finding safe stocks with the potential to deliver outsized gains can be challenging, but this list of names is certainly a good place to start.

11 Safe Stocks for Superior Gains

Abbott (ABT) delivered earnings and revenue surprises of 15.84% and 5.13%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Abbott (ABT) Surpasses Q2 Earnings and Revenue Estimates

Abbott Laboratories (NYSE: ABT) Q2 profit more than doubled to $2.1 billion due to strength in its diagnostics business and a rebound in medical device sales. As curbs lift and vaccinations gather, demand for medical devices is returning as more people opt for non-urgent procedures.

Abbott Q2 Profit More Than Doubles As Medical Device Sales Rebound

Shares of Abbott Laboratories edged up 0.2% in premarket trading Thursday, after the medical devices, diagnostics and nutrition company reported second-quarter profit and sales that rose above expectations, with beats in all of its major business segments. Net income more than doubled, to $1.19 billion, or $1.17 a share, from $537 million, or 57 cents a share, in the year-ago period.

Abbott Labs stock gains after profit more than doubles, sales rise above expectations

Shares of Abbott Laboratories (NYSE:ABT) decreased 0.2% in pre-market trading after the company reported Q2 results. Quarterly Results Earnings per share rose 105.26% over the past year to $1.17, which beat the estimate of $1.02.

Abbott Laboratories: Q2 Earnings Insights

Abbott Laboratories quarterly profit more than doubled on Thursday, due to strength in its diagnostics business and a rebound in medical devices sales.

Abbott second-quarter profit surges as medical device sales rebound

ABBOTT PARK, Ill., July 22, 2021 /PRNewswire/ -- Abbott (NYSE: ABT) today announced financial results for the second quarter ended June 30, 2021.

Abbott Reports Second-Quarter 2021 Results

Abbott Laboratories (NYSE:ABT) announces its next round of earnings this Thursday, July 22. Here is Benzinga's everything-that-matters guide for this Thursday's Q2 earnings announcement.

Earnings Preview: Abbott Laboratories

Abbott is scheduled to report its Q2 2021 results on Thursday, July 22. We expect Abbott to report revenues and earnings above the consensus estimates, driven by continued growth in diagnostics business, along with a rebound in demand for medical devices.

Will Abbott Stock Rise Post Q2?

Else Nutrition Holdings Inc. (CVE:BABY) (OTCMKTS:BABYF) (FRA:0YL.F) has announced two strategic additions to the company's executive team, with the appointment of Simeon Saunders as VP Global Medical Marketing and Scientific Affairs and Mike Glick as GM and VP Else North America, both of whom are former executives with Abbott Laboratories. “We are extremely delighted by the addition of Mike and Simeon to the Company.

News for Abbott Labs Stock (ABT)